

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb30437</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>Silencing SALL-4 Gene by Transfecting Small Interfering RNA with Targeted Aminoglycoside-Carboxyalkyl Polyethylenimine Nano-Polyplexes Reduced Migration of MCF-7 Breast Cancer Cells</article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Noruzi</surname><given-names>Somaye</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Vatanchian</surname><given-names>Mehran</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Azimian</surname><given-names>Amir</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Niroomand</surname><given-names>Arash</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Salarinia</surname><given-names>Reza</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Oroojalian</surname><given-names>Fatemeh</given-names></name></contrib></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>13</volume>
      <issue>1</issue>
      <fpage>2</fpage>
      <lpage>8</lpage>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>5</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>8</month>
          <year>2020</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;Background: The application of non-viral systems for delivering genes to cells is becoming a very interesting issue, especially in the treatment of neoplasms such as Breast Cancer (BC). Polymer-based non-viral systems are safe and feasible gene carriers to be used in targeted cancer therapy. SALL4 gene encodes a transcription factor and is overexpressed in some cancers.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;Methods: In this study, carboxyalkylated-PEI25 (25 kDa) was used to deliver plasmids expressing SALL4-siRNA into MCF-7 cells. DLS and AFM were applied to determine the size of nanoparticles. The MTT method was used to assess cytotoxicity, and the efficiency of transfection was confirmed both qualitatively and quantitatively. Finally, the effect of silencing SALL4 was investigated on the migration of MCF7 cells using the scratch test.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;Results: The results showed that transferring the SALL4-siRNA using PEI25G10C50 reduced the expression of the corresponding transcription factor by 14 folds which attenuated the migration of MCF-7 cells by 58%. &lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;Conclusion: In conclusion, PEI25G10C50 can serve as an effective gene delivery system for treating BC by targeting SALL-4.&lt;/span&gt;&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
